Carlsmed, Inc. (CARL) Stock Price & Analysis
Carlsmed, Inc. (CARL) is trading at USD 17.44, down 1.72% today, as of November 18, 2026 at 20:53 UTC (US market open; quotes may be delayed), according to Nexqual market data.
CARL last closed at USD 17.74; today's session has ranged USD 17.32–18.26 on volume of 97,166 shares. Market capitalization is $477.79M, with a 52-week range of USD 8.5–19.15 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CARL.md
Key facts (CARL)
- Last four reported quarters (through Sep 30, 2026): revenue $71.8M, net income -$40.1M (-55.8% margin), free cash flow -$34.9M (SEC filings).
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $29K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.60 on a 1–5 scale) (5 analysts), mean target USD 22 (range 18–26).
- Total return with dividends: 1Y +44.8% vs S&P 500 +11.8%; 5Y +22.3% vs S&P 500 +66.5%.
- Latest earnings report: 2026-11-10 (next date not yet announced).
- Dividend: CARL paid no cash dividend in the last five years.
- Short interest: 12.04% of float (as of 2026-10-30), 15.1 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CARL)
| USD | FY2024 | FY2025 | TTM |
|---|---|---|---|
| Revenue | $27.2M | $50.5M | $71.8M |
| Gross profit | $20.0M | $38.0M | — |
| Operating income | -$24.1M | -$30.6M | -$42.3M |
| Net income | -$24.3M | -$29.6M | -$40.1M |
| EPS (diluted) | -$6.11 | -$2.12 | — |
| Free cash flow | -$25.6M | -$29.6M | -$34.9M |
| Gross margin | 73.8% | 75.3% | — |
| Operating margin | -88.8% | -60.5% | -59.0% |
| Net margin | -89.3% | -58.7% | -55.8% |
| Revenue growth | — | +85.9% | — |
| Cash + short-term investments | $40.1M | $110M | — |
| Total debt | $15.4M | $15.3M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (CARL)
P/S 6.8x · EV/Sales 6.2x · P/B 6.4x · FCF yield -7.18% · Earnings yield -8.24% · Net cash $44.5M · EV $442M
Insider sales (SEC Form 4, open-market, last ~7 months) (CARL)
4 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | Bertolini Jeffrey | Chief Operating Officer | 747 | $11K | 3.2% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-10-30 | Bertolini Jeffrey | Chief Operating Officer | 243 | $4K | 1.1% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Bertolini Jeffrey | Chief Operating Officer | 747 | $11K | 3.2% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-30 | Bertolini Jeffrey | Chief Operating Officer | 243 | $3K | 1.1% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CARL)
Consensus Buy (mean 1.60 on a 1–5 scale), 5 analysts; mean target USD 22 (low 18, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-11 | Truist Securities | Target raised | Buy | $20 → $23 |
| 2026-11-11 | Needham | Target raised | Buy | $17 → $22 |
| 2026-11-11 | BTIG | Target raised | Buy | $24 → $26 |
| 2026-10-12 | BTIG | Target raised | Buy | $23 → $24 |
| 2026-09-28 | BTIG | Reiterated | Buy | $23 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $18 → $20 |
Total return (dividends reinvested) (CARL)
| 1Y (from 2025-11-18) | 5Y (from 2025-07-21) | |
|---|---|---|
| Total return | +44.8% | +22.3% |
| S&P 500 (SPY) | +11.8% | +66.5% |
| Per year | +44.9% | +16.4% |
| Volatility (annualized) | 74.6% | 65.4% |
| Max drawdown | -48.0% (Dec 2025→Apr 2026) | -45.1% (Nov 2025→Apr 2026) |
Dividends (CARL)
CARL paid no cash dividend in the last five years.
Short interest (CARL)
1,241,498 shares sold short, 12.04% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,053,927 shares (+17.8%). Days to cover: 15.1 (short shares ÷ average daily volume).
CARL earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$0.11 | −$0.38 | Beat +71.1% | — |
| — | Quarter ended Jun 30, 2026 | −$0.39 | −$0.39 | In line | — |
| — | Quarter ended Mar 31, 2026 | −$0.26 | −$0.39 | Beat +33.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.29 | −$0.43 | Beat +32.6% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CARL recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 10, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 10, 2026 | 8-K | Quarterly results |
| Sep 30, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “Departure of Chief Financial Officer On September 28, 2026, Carlsmed, Inc. (the "Company") announced that Leo Greenstein has departed his role as the Company's Chief Financial Officer, effective September 25, 2026 (the "Separation Date"). The Company appreciates Mr. Greenstein's contributions and wishes him well in his future endeavors. Mr. Greenstein's departure is not a result of any disagreement with the Company's independent auditors or any member of management on any matter of accounting principles or…” |
| Sep 8, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “On September 4, 2026, the Board of Directors of Carlsmed, Inc. (the "Company") appointed Jeffrey Bertolini as Chief Operating Officer of the Company, effective September 8, 2026. Mr. Bertolini, age 60, has served as the Company's Senior Vice President, Operational Excellence since March 2025. Previously, Mr. Bertolini was Vice President of Advanced Manufacturing Technologies of the Company from September 2024 to March 2025. Before joining the Company, Mr. Bertolini was Senior Vice President, Operations &…” |
| Aug 5, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 5, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CARL suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Johnson & Johnson (JNJ) | “Our products currently compete with stock implants manufactured or developed by other companies, including Medtronic PLC, Johnson & Johnson, and Globus Medical Inc. Some of these competitors are large, well-capitalized companies with greater market share and resources than we have.” |
Quoted from the company's 10-K filed Feb 25, 2026.
CARL customer concentration
In the quarter ended Mar 31, 2025, a single direct customer accounted for 10% of CARL's revenue. The company does not name this customer in the filing. Source: the company's 10-Q filed May 5, 2026.
CARL company outlook (results filed Nov 10, 2026)
- “Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
CARL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.39 | $-0.40 | +$0.01 | $19.2M | 2 |
| Next quarter (ends Dec 2026) | $-0.35 | $-0.30 | −$0.04 | $24.3M | 1 |
| Current fiscal year (ends Dec 2026) | $-1.51 | $-1.41 | −$0.10 | $79.3M | 1 |
| Next fiscal year (ends Dec 2027) | $-1.56 | $-1.38 | −$0.18 | $111.9M | 1 |
Key Statistics (as of November 18, 2026 at 20:53 UTC)
| Price | USD 17.44 |
|---|---|
| Change | ▼ 1.72% (down) |
| Previous Close | USD 17.74 |
| Open | USD 17.77 |
| Day Range | USD 17.32 – 18.26 |
| 52-Week Range | USD 8.5 – 19.15 |
| Volume | 97,166 shares |
| Market Cap | $477.79M |
| Exchange | NMS |
Technical Analysis (CARL)
Nexqual's technical model rates CARL "STRONG BUY" based on 5 bullish and 0 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.24 (neutral) |
| vs SMA50 | Above (USD 15.1) |
| MACD | 0.75 (positive) |
Analyst Ratings (CARL)
Wall Street analysts rate CARL "Buy" based on 5 analysts, with a mean price target of USD 22 (range USD 18–26), per Nexqual as of November 18, 2026 at 20:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 22 |
| High Target | USD 26 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (CARL)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.39 |
| Revenue Estimate | $19.16M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -0.11 vs est -0.39 ▲ beat |
| 2026-06-30 | USD -0.39 vs est -0.4 ▲ beat |
| 2026-03-31 | USD -0.26 vs est -0.4 ▲ beat |
| 2025-12-31 | USD -0.29 vs est -0.43 ▲ beat |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financials & Fundamentals (CARL)
| Total Revenue | $71.78M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +64.90% |
| Gross Margin | +76.96% |
| Operating Margin | -58.98% |
| Profit Margin | -55.82% |
| ROE | -43.95% |
| Debt / Equity | 0.29 |
| Current Ratio | 5.79 |
| Total Cash | $80.21M |
| Total Debt | $21.79M |
| Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K) | -$34.92M (-48.6% of revenue) |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financial Health Score (CARL)
Nexqual rates Carlsmed, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:53 UTC.
| Growth | Strong — Revenue +60% (last 4 quarters to Sep 2026 vs the 4 before, SEC) |
|---|---|
| Profitability | Solid — Gross margin 77%, operating -59% (last 4 quarters to Sep 2026, SEC) |
| Balance Sheet | Strong — $60M cash and investments vs $15M debt (Sep 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$35M (last 4 quarters to Sep 2026, SEC), burning cash |
| Efficiency | Critical — ROE -53%, ROA -34.8% (last 4 quarters, SEC) |
Ownership (CARL)
| Insider Ownership | +43.27% |
|---|---|
| Institutional Ownership | +44.03% |
| Shares Outstanding | 27.40M |
| Float | 15.75M |
| Short % of Float | +12.04% |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Leadership (CARL)
Carlsmed, Inc. is led by Michael John Cordonnier, Co-Founder, Chairman, CEO & President, per Nexqual as of November 18, 2026 at 20:53 UTC.
| Co-Founder, Chairman, CEO & President | Michael John Cordonnier |
|---|---|
| Co-Founder, Chief Intellectual Property Officer & Director | Niall Patrick Casey |
| Chief Financial Officer | Richard J. Heppenstall |
| Chief Operating Officer | Jeff Bertolini |
| Chief Technology Officer | Shariq Hussain |
Major Backers & Investors (CARL)
Notable institutional backers of Carlsmed, Inc. include Jupiter Topco LLC, JANUS INVESTMENT FUND-Janus Henderson Venture Fund, Parkman Healthcare Partners LLC, according to Nexqual as of November 18, 2026 at 20:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 4.57% |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 2.23% |
| Parkman Healthcare Partners LLC | 2.18% |
| Pier Capital, LLC | 1.89% |
| Millennium Management | 1.08% |
| Palumbo Wealth Management Llc | 0.97% |
| Russell Investments Group, Ltd. | 0.94% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.12% |
| Vanguard Group | 1.03% |
| Geode Capital | 0.86% |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
From Carlsmed, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- The aprevo Technology Platform represents an end-to-end, integrated digital technology platform designed to deliver better surgical results, reduce the need for revision surgery, and improve long-term outcomes.
- In November 2024, we received FDA 510(k) clearance for our aprevo interbody implants for cervical interbody fusion surgeries after previously receiving FDA Breakthrough Device Designation for this technology, and in July 2025, we successfully completed the first in-human personalized cervical procedure in the United States using our aprevo Technology Platform.
- We have generated limited early sales of aprevo interbody implants for use in cervical spine fusion surgery following a commercial launch in December 2025 and expect to more broadly commercialize the aprevo cervical platform, including the anticipated commercial launch of our corra Cervical Plating System, in 2026.
- We estimate that the total addressable market for aprevo cervical devices in the United States. is approximately $6 billion, based on our current average revenue per cervical fusion procedure and our estimate (informed by projections contained in the SmartTRAK Report) that approximately 372,600 cervical fusion surgeries were performed in the United States in 2025.
Partnerships
- In August 2025, in the CMS Final Rule, the Centers for Medicare and Medicaid Services ("CMS") finalized X-codes for the use of custom-made anatomically designed interbody fusion devices for cervical spine fusion surgeries and established a New Technology Add-on Payment ("NTAP") of up to $21,125 additional reimbursement to hospitals for qualifying inpatient cervical spine fusion procedures.
- Our platform begins by analyzing each patient's pathology and spinal anatomy, relying on standard diagnostic imaging to create a 3D model that is then used to identify, in collaboration with the health care provider, the corrections necessary to bring the spine within alignment.
Legal & Regulatory Risks (Item 1A, quoted)
- The continued commercialization of the aprevo Technology Platform depends in part on the extent to which third-party payors provide coverage and adequate reimbursement levels. Failure to obtain and maintain coverage and adequate reimbursement for aprevo interbody implants could limit our ability to market them and decrease our ability to generate revenue.
- We are subject to certain federal and state fraud and abuse laws and transparency laws, and any failure to comply could subject us to substantial penalties or other adverse consequences.
- Our employees, independent sales agents, consultants, and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
- We are exposed to the risk that our employees, independent sales agents, consultants, and other commercial partners and business associates may engage in fraudulent or illegal activity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HTFL | Heartflow, Inc. | USD 46.01 | ▼ 2.25% |
| EVH | Evolent Health, Inc | USD 3.95 | ▼ 14.5% |
| NRC | NRC Health | USD 26.06 | ▲ 0.68% |
| CTEV | Claritev Corporation | USD 21.95 | ▼ 4.35% |
| SOPH | SOPHiA GENETICS SA | USD 7.47 | ▲ 0.27% |
| PHR | Phreesia, Inc. | USD 12.31 | ▼ 1.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt